Baricitinib prevents GvHD by increasing Tregs via JAK3 and treats established GvHD by promoting intestinal tissue repair via EGFR

Sena Kim; Kidist Ashami; Sora Lim; Karl Staser; Kiran Vij; Srikanth Santhanam; Julie Ritchey; Sarah Peterson; Feng Gao; Matthew A. Ciorba; Matthew L. Cooper; John F. DiPersio; Jaebok Choi

doi:10.1038/s41375-021-01360-9

Baricitinib prevents GvHD by increasing Tregs via JAK3 and treats established GvHD by promoting intestinal tissue repair via EGFR

Sena Kim, Kidist Ashami, Sora Lim, Karl Staser, Kiran Vij, Srikanth Santhanam, Julie Ritchey, Sarah Peterson, Feng Gao, Matthew A. Ciorba, Matthew L. Cooper, John F. DiPersio, Jaebok Choi

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Original language	English
Pages (from-to)	292-295
Number of pages	4
Journal	Leukemia
Volume	36
Issue number	1
DOIs	https://doi.org/10.1038/s41375-021-01360-9
State	Published - Jan 2022

Access to Document

10.1038/s41375-021-01360-9

Cite this

@article{988dc25ca95149c0ac1a4eac82bc4c0c,

title = "Baricitinib prevents GvHD by increasing Tregs via JAK3 and treats established GvHD by promoting intestinal tissue repair via EGFR",

author = "Sena Kim and Kidist Ashami and Sora Lim and Karl Staser and Kiran Vij and Srikanth Santhanam and Julie Ritchey and Sarah Peterson and Feng Gao and Ciorba, {Matthew A.} and Cooper, {Matthew L.} and DiPersio, {John F.} and Jaebok Choi",

note = "Funding Information: JC received honorarium from Incyte Corporation, received research funding from Mallinckrodt Pharmaceuticals, and served as a consultant for Daewoong Pharmaceutical. JFD served on advisory boards for Incyte Corporation, CellWorks, Macrogenics, Amphivena, Arch, Rivervest, and Bioline and is a co-Founder of Magenta Therapeutics and WUGen. MLC is a co-Founder and Chief Scientific Officer of WUgen. MAC previously had research grants from Incyte Corporation. The other authors declare no conflict of interest. Funding Information: JC is supported by Amy Strelzer Manasevit Research Program (the Be The Match Foundation and the National Marrow Donor Program), Alvin J. Siteman Cancer Center Siteman Investment Program (supported by the Foundation for Barnes-Jewish Hospital Cancer Frontier Fund, National Cancer Institute Cancer Center Support Grant, P30 CA091842, and Barnard Trust), Bigelow Aerospace (OTM 13489), Washington University SPORE-CDP in Leukemia (P50 CA171963), Washington University DDRCC grant (P30 DK052574), and the Bryan Thomas Campbell Foundation. JFD is supported by Bigelow Aerospace (OTM 13489), Washington University NCI/NIH SPORE in Leukemia (P50 CA171963), NCI Outstanding Investigator Award (R35 CA210084), and the Bryan Thomas Campbell Foundation. KA is supported by Washington University SPORE Diversity Program (P50 CA171963). MAC is supported by R01DK109384 and The Lawrence C. Pakula MD IBD Research Fund at Washington University.",

year = "2022",

month = jan,

doi = "10.1038/s41375-021-01360-9",

language = "English",

volume = "36",

pages = "292--295",

journal = "Leukemia",

issn = "0887-6924",

number = "1",

}

TY - JOUR

T1 - Baricitinib prevents GvHD by increasing Tregs via JAK3 and treats established GvHD by promoting intestinal tissue repair via EGFR

AU - Kim, Sena

AU - Ashami, Kidist

AU - Lim, Sora

AU - Staser, Karl

AU - Vij, Kiran

AU - Santhanam, Srikanth

AU - Ritchey, Julie

AU - Peterson, Sarah

AU - Gao, Feng

AU - Ciorba, Matthew A.

AU - Cooper, Matthew L.

AU - DiPersio, John F.

AU - Choi, Jaebok

N1 - Funding Information: JC received honorarium from Incyte Corporation, received research funding from Mallinckrodt Pharmaceuticals, and served as a consultant for Daewoong Pharmaceutical. JFD served on advisory boards for Incyte Corporation, CellWorks, Macrogenics, Amphivena, Arch, Rivervest, and Bioline and is a co-Founder of Magenta Therapeutics and WUGen. MLC is a co-Founder and Chief Scientific Officer of WUgen. MAC previously had research grants from Incyte Corporation. The other authors declare no conflict of interest. Funding Information: JC is supported by Amy Strelzer Manasevit Research Program (the Be The Match Foundation and the National Marrow Donor Program), Alvin J. Siteman Cancer Center Siteman Investment Program (supported by the Foundation for Barnes-Jewish Hospital Cancer Frontier Fund, National Cancer Institute Cancer Center Support Grant, P30 CA091842, and Barnard Trust), Bigelow Aerospace (OTM 13489), Washington University SPORE-CDP in Leukemia (P50 CA171963), Washington University DDRCC grant (P30 DK052574), and the Bryan Thomas Campbell Foundation. JFD is supported by Bigelow Aerospace (OTM 13489), Washington University NCI/NIH SPORE in Leukemia (P50 CA171963), NCI Outstanding Investigator Award (R35 CA210084), and the Bryan Thomas Campbell Foundation. KA is supported by Washington University SPORE Diversity Program (P50 CA171963). MAC is supported by R01DK109384 and The Lawrence C. Pakula MD IBD Research Fund at Washington University.

PY - 2022/1

Y1 - 2022/1

UR - http://www.scopus.com/inward/record.url?scp=85111649021&partnerID=8YFLogxK

U2 - 10.1038/s41375-021-01360-9

DO - 10.1038/s41375-021-01360-9

M3 - Article

C2 - 34304247

AN - SCOPUS:85111649021

SN - 0887-6924

VL - 36

SP - 292

EP - 295

JO - Leukemia

JF - Leukemia

IS - 1

ER -

Baricitinib prevents GvHD by increasing Tregs via JAK3 and treats established GvHD by promoting intestinal tissue repair via EGFR

Access to Document

Other files and links

Cite this